cofrogliptin

Cofrogliptin (HSK7653) is a novel, ultralong-acting oral dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the treatment of type 2 diabetes mellitus. It is characterized by its long plasma half-life and supports a dosing regimen of once every two weeks. Cofrogliptin works by inhibiting DPP-4, thereby increasing plasma concentrations of incretin hormones such as GLP-1 and GIP, which promote insulin secretion and improve glycemic control. The drug demonstrates potent DPP-4 inhibition (>80% for 14 days), significant reductions in HbA1c levels at recommended doses (10 mg and 25 mg), and favorable safety/tolerability profiles in clinical studies. Renal excretion is the primary elimination pathway for cofrogliptin[1][2][3][6].

Brand names

倍长平

Other names

cofrogliptinHaisco HSK7653